BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Figure out How to Amplify the Resale Worth of Your Kona SUV- Exploring the Difficulties of Co-Nurturing: Individual Bits of knowledge
- Figure out How to Remain Persuaded During Your Internet based Degree Program
- The Solution to Defeating Tarrying: Systems for Expanded Efficiency
- Step by step instructions to Think about Disc Rates Across Various Banks
- Exploring the Mind boggling Universe of Connections: Individual Bits of knowledge
- Revealing the Incomparable Realms: An Excursion through Power and Inheritance
- Significant Elements to Consider Prior to Applying for a Mastercard: 6 Vital Contemplations
- The most effective method to Remain Ahead in the Most recent Advanced Patterns with a Web based Advertising Degree
